Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Immune Design studies combinatorial regimen CMB-305 for NY-ESO-1-expressing cancers

March 16, 2015

Oxis Biotech licenses rights to antibody-drug conjugates for cancer

March 16, 2015

BriaCell Therapeutics submits phase I/II protocol to the FDA

March 13, 2015

University of Toronto divulges new anti-Frizzled antibodies

March 12, 2015

FDA approves Unituxin for pediatric patients with high-risk neuroblastoma

March 11, 2015

Madison Vaccines confirms program expansions for prostate cancer vaccines

March 11, 2015

Heat Biologics receives FDA fast track designation for HS-410 in combination with BCG

March 10, 2015

arGEN-X exercises option to license antibody candidate for cancer immunotherapy

March 6, 2015

FDA approves Opdivo for metastatic squamous NSCLC

March 5, 2015

BMS gains option to license Prostvac from Bavarian Nordic

March 5, 2015

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...